Axsome Therapeutics Inc (AXSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 4:15 PM ET
Axsome Therapeutics Inc (AXSM) Statistics
Axsome Therapeutics (AXSM) has a market cap of $7.45B and an enterprise value of $7.35B. Revenue grew 54.16% over the last 12 months from the 12 months before. Its share count is up 4.84% from a year earlier.
Total Valuation
Enterprise value is 1.41% below the market cap, as cash exceeds debt.
| Market Cap | $7.45B |
|---|---|
| Enterprise Value | $7.35B |
| Latest price (Nov 17, 2026) | $135.95 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.2x and 67.6x. Its year-end P/S ranged from 10.5x to 64.8x from 2022 to 2025.
| P/S Ratio | 8.2x |
|---|---|
| Forward P/S | 7.8x |
| P/B Ratio | 67.6x |
| P/TBV Ratio | 123.7x |
Price Statistics
The stock is down 2.68% over 52 weeks and trades 19.37% below its 50-day average.
| Beta (1Y) | 0.72 |
|---|---|
| 52-Week Change | -2.68% |
| 1-Month Change | -12.75% |
| 3-Month Change | -37.69% |
| 6-Month Change | -40.02% |
| 5-Year Change | +275.14% |
| 10-Year Change | +2055.67% |
| Total Return (1Y) | -2.68% |
| Total Return (3Y CAGR) | +31.42% |
| Total Return (5Y CAGR) | +30.76% |
| Return vs SPY (1Y) | -19.38% |
| Max Drawdown (1Y) | -49.13% |
| Max Drawdown (3Y) | -49.13% |
| Sharpe Ratio (1Y) | -0.18 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $168.62 |
| 200-Day Average | $196.56 |
| 52-Week Range | $123.00 to $260.19 |
| RSI (14 Days) | 36.6 |
| Average Volume (20 Days) | 1.14M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.42x current liabilities, and total debt is 1.98x shareholder equity.
| Current Ratio | 1.42x |
|---|---|
| Quick Ratio | 1.34x |
| Debt / Equity | 1.98x |
Returns and Efficiency
Return on invested capital is -48.11% over the last 12 months, against a 5-year average of -90.61%.
| Return on Equity (ROE) | -149.19% |
|---|---|
| Return on Assets (ROA) | -19.02% |
| Return on Invested Capital (ROIC) | -48.11% |
| Return on Capital Employed (ROCE) | -47.63% |
| ROA (5Y Average) | -64.55% |
| ROIC (5Y Average) | -90.61% |
| Asset Turnover | 1.16x |
| Inventory Turnover | 1.45x |
| Receivables Turnover | 2.79x |
| Cash Conversion Cycle | -2137 days |
Scores
AXSM has an Altman Z-Score of 4.26, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.26 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $865.27M over the last 12 months.
| Revenue | $865.27M |
|---|---|
| Revenue Growth (YoY) | +54.16% |
| Gross Profit | $806.85M |
| Operating Income | -$151.03M |
| Pretax Income | -$156.65M |
| Net Income | -$157.29M |
| EBITDA | -$139.79M |
| EBIT | -$151.03M |
| Reported EPS (TTM) | -$3.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 12.75% of the $826.77M in total assets.
| Cash and Equivalents | $313.86M |
|---|---|
| Total Debt | $208.49M |
| Net Cash | $105.37M |
| Net Cash Per Share | $2.01 |
| Working Capital | $214.92M |
| Shareholder Equity | $105.43M |
| Book Value Per Share | $2.01 |
| Tangible Book Value | $57.64M |
| Tangible Book Per Share | $1.10 |
| Total Assets | $826.77M |
| Total Liabilities | $721.34M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $839.00K of capital spending, operating cash flow left -$82.61M of free cash flow.
| Operating Cash Flow | -$81.77M |
|---|---|
| Capital Expenditures | $839.00K |
| Free Cash Flow | -$82.61M |
| FCF Per Share | -$1.58 |
| Depreciation and Amortization | $11.24M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -17.45%.
| Gross Margin | 93.25% |
|---|---|
| Operating Margin | -17.45% |
| Pretax Margin | -18.10% |
| Net Margin | -18.18% |
| EBITDA Margin | -16.16% |
| EBIT Margin | -17.45% |
| FCF Margin | -9.55% |
Growth
Revenue grew 133.68% a year over 3 years.
| Revenue Growth (3Y CAGR) | +133.68% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -34.26% |
| Tangible Book Per Share Growth (2Y CAGR) | -48.44% |
Dividends and Yields
AXSM does not pay a dividend. Its free cash flow yield is -1.16%.
| FCF Yield | -1.16% |
|---|---|
| Buyback Yield | -1.44% |
| Shareholder Yield | -1.44% |
Peer Position
Against 3 similar companies, AXSM has the 3rd highest P/S.
P/S RatioPeer median 11.1x
ROICPeer median -74.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 8.2x vs 11.1x median |
|---|---|
| ROIC | -48.11% vs -74.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +54.16% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 50.66% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +50.66% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AXSM
What is AXSM's market cap?
Axsome Therapeutics has a market cap of $7.45B. Its enterprise value, which adds debt and subtracts cash, is $7.35B.
How many shares of AXSM are outstanding?
Axsome Therapeutics has 52.45M shares outstanding. The count is up 4.84% from a year earlier.
Does AXSM pay a dividend?
No. Axsome Therapeutics does not pay a dividend.
How much debt does AXSM have?
Axsome Therapeutics has $208.49M of total debt and $313.86M of cash and equivalents, a net cash position of $105.37M.
AXSM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors